← Eichor
Study identifier: NCT06720545 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy

Condition: Obstructive Sleep Apnea · Obstructive Sleep Apnea of Adult  ·  Sponsor: Columbia University

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Hypoglossal nerve stimulation (HGNS) is an implantable therapy that treats obstructive sleep apnea. The study will evaluate the effect of this treatment on cardiovascular and metabolism-related measures to see if it affects patients' risk of medical problems associated with obstructive sleep apnea (OSA).

This description comes directly from the study's public registry record.

Talk to the study team

Otolaryngology Research Group  ·  646-317-3252  ·  otosleepresearch@cumc.columbia.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Columbia University Medical CenterNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06720545